AB 329
Alternative Names: DS 1205; DS 1205b; DS-1205cLatest Information Update: 28 Oct 2024
At a glance
- Originator Daiichi Sankyo Company
- Developer AnHeart Therapeutics; Daiichi Sankyo Company
- Class Amides; Antineoplastics; Dioxanes; Fluorobenzenes; Phenyl ethers; Pyrans; Pyridines; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
- Research Ovarian cancer
- No development reported Haematological malignancies; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 10 Apr 2024 AnHeart Therapeutics has been acquired by Nuvation Bio